TD Cowen restated a buy rating on Editas Medicine, which also disclosed insider sales to the SEC.
1 report, 1 independent
Updated Aug 10
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
TD Cowen restated a buy rating on Editas Medicine, which also disclosed insider sales to the SEC.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Editas Medicine
discovery-phase pharmaceutical company
Nothing else this week.
-
TD Cowen
American investment bank
Related events
- TD Cowen provided analyst ratings and price targets for Ardelyx, accompanied by required stock transaction filings with the SEC.
- TD Cowen upgraded Crescent Biopharma shares to 'strong-buy', while Wedbush reiterated 'outperform', and a CEO sold shares under a 10b5-1 plan.
- TD Cowen issued a buy rating and price target for Evolv Technologies Holdings, Inc.
- TD Cowen boosted its price objective on Elevance Health, while the National Pension Service reduced its holdings and filed 13F with the SEC.
- Raymond James Financial and TD Cowen issued rating updates for GDS, alongside an insider transaction disclosure filed with the SEC.